ABOUT SEVITERONEL VT-464

-mutated tumors. Nevertheless, only a fraction of those people responds to immune checkpoint or PARP inhibitors and also individuals that do react generally create resistance and relapse.Mechanistically, we report differential binding of AR to focus on genes within the presence of enzalutamide and seviteronel, suggesting diverse mechanisms of actio